Remove Gene Editing Remove Genome Remove Licensing
article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA.

article thumbnail

ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical

BioTech 365

ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical License to Nobel prize winning CRISPR technology supports internal research and development DUBLIN, Ireland–(BUSINESS WIRE)–ERS Genomics Limited, which was formed … Continue reading (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolio

The Pharma Data

Vivlion holds an exclusive license to Goethe University of Frankfurt’s proprietary 3Cs technology for the production of next generation 3Cs CRISPR/Cas gRNA libraries. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. “The

Genome 52
article thumbnail

ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement

BioTech 365

ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement ZeClinics is applying CRISPR technology to create gene edited zebrafish disease models DUBLIN & BARCELONA, Spain–(BUSINESS WIRE)–ERS Genomics Limited, which was formed to provide … Continue reading → (..)

Genome 40
article thumbnail

 ERS Genomics Announces Agreement with FASMAC to Commercialize CRISPR/Cas9 Research Reagents in Japan

BioTech 365

Food analysis and biotechnology company licenses gene editing technology DUBLIN & KANAGAWA, Japan–(BUSINESS WIRE)–ERS Genomics Limited (“ERS”), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has … Continue (..)

Genome 40
article thumbnail

Roche puts $70m into ArsenalBio’s programmable T-cell platform

pharmaphorum

” ArsenalBio’s platform makes use of automation, large-scale genome engineering, using technologies like CRISPR-based gene-editing, and machine learning and artificial intelligence algorithms to design, build, and test cell therapies.

article thumbnail

LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)

The Pharma Data

It may also allow for priority or rolling review of a company’s Biologics License Application (BLA). LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination.